Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Zimmer Biomet Holdings Inc    ZBH

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Zimmer Holdings, Inc. : Zimmer Receives FDA Warning on Certain Hip Implants

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/02/2012 | 12:40am CET

--Zimmer says FDA inspection of Puerto Rico plant turned up concerns about manufacturing of certain implants

--FDA in letter noted manufacturing, testing issues related to Trilogy Acetabuar System products, company says

--Zimmer says it is notifying customers of manufacturing issue, but hasn't withdrawn any products

(Adds context on metallic spikes in fourth paragraph and a no comment from Zimmer in seventh paragraph.)

 
   By Kristin Jones 
 

Zimmer Holdings Inc. (ZMH) said a U.S. Food and Drug Administration inspection of its plant in Puerto Rico turned up concerns about the manufacturing of certain hip implants.

The orthopedic maker's Zimmer Inc. subsidiary received a warning letter from the FDA dated Sept. 19, the company said in a regulatory filing Monday. In the letter, the FDA noted manufacturing and testing issues related to the company's Trilogy Acetabular System products, which are implanted in hip-replacement surgery.

Specifically, the U.S. drug regulator noted that Zimmer hadn't implemented a testing mechanism to show that its products met design specifications. The company also hadn't validated the effect of certain manufacturing operations on Trilogy products that incorporate metallic spikes.

Spikes are used to connect the hip replacement cup to a patient's bone when cement and screws are deemed insufficient.

The FDA requires that drug and medical-device makers undertake steps to ensure the quality of the design and manufacture of its products, known as process validation.

Zimmer said it is notifying customers of the manufacturing issue, but that it hasn't withdrawn any products. The company also said it previously suspended release of the spiked products, pending validation of the processes cited in the letter, and expects to complete validation in the next few weeks.

A Zimmer spokesman declined to comment further.

Shares gained 11 cents to $67.98 in after-hours trading. Through Monday's close, the stock was up 27% so far this year.

--Joseph Walker contributed to this article.

Write to Kristin Jones at kristin.jones@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ZIMMER BIOMET HOLDINGS INC
12/09 ZIMMER BIOMET HOLDINGS INC : Khang & Khang LLP Announces Securities Class Action..
12/09 Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zimmer Biome..
12/09 ZIMMER BIOMET HOLDINGS INC : Lundin Law PC Announces Securities Class Action Law..
12/08 ZIMMER BIOMET HOLDINGS INC : Khang & Khang LLP Announces Securities Class Action..
12/07 ZIMMER BIOMET : Named "2017 Top Employer" in China
12/07 ZIMMER BIOMET : Pain Management Medical Devices Gain Popularity
12/07 ZIMMER BIOMET HOLDINGS INC : Lundin Law PC Announces Securities Class Action Law..
12/06 ZIMMER BIOMET HOLDINGS INC : Khang & Khang LLP Announces Securities Class Action..
12/06 ZIMMER BIOMET : Dec 6, 2016 Zimmer Biomet Prices Offering of Euro-Denominated Se..
12/06 ZIMMER BIOMET : Dec 6, 2016 Zimmer Biomet Announces the Pricing Terms of Its Cas..
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
12/08 MEDTRONIC : China says fines Medtronic local unit 118.5 million yuan for price f..
11/22DJMEDTRONIC : Cuts Guidance on Sluggish Revenue
11/22DJMEDTRONIC : Cuts Guidance on Sluggish Revenue -- 2nd Update
11/22DJMEDTRONIC : Cuts Guidance on Sluggish Revenue
11/15 EXCLUSIVE : EU regulators seen clearing $25 billion Abbott, St Jude deal
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
12/08 Large-cap stocks with the most upside next year, according to sell-side
11/30 A Cold Shoulder For Cloud Peak - Cramer's Lightning Round (11/29/16)
11/23 RTI Surgical Is An Undervalued Acquisition Target
11/21 Zimmer Biomet initiates offer to buy up to $1.1B in outstanding debt
11/15 Preliminary data shows Zimmer Biomet's autologous bone marrow aspirate extend..
Advertisement
Financials ($)
Sales 2016 7 647 M
EBIT 2016 2 420 M
Net income 2016 633 M
Debt 2016 10 294 M
Yield 2016 0,88%
P/E ratio 2016 47,38
P/E ratio 2017 16,77
EV / Sales 2016 4,10x
EV / Sales 2017 3,78x
Capitalization 21 076 M
More Financials
Chart ZIMMER BIOMET HOLDINGS INC
Duration : Period :
Zimmer Biomet Holdings Inc Technical Analysis Chart | ZBH | US98956P1021 | 4-Traders
Full-screen chart
Technical analysis trends ZIMMER BIOMET HOL...
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 132 $
Spread / Average Target 25%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David C. Dvorak President, Chief Executive Officer & Director
Larry C. Glasscock Non-Executive Chairman
Robin T. Barney Senior VP-Global Operations & Logistics
Daniel P. Florin Chief Financial Officer & Senior Vice President
David J. Kunz VP-Global Quality, Clinical & Regulatory Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ZIMMER BIOMET HOLDINGS..1.81%21 076
MEDTRONIC PLC-4.64%100 713
BAXTER INTERNATIONAL I..17.54%24 389
C R BARD INC12.76%15 929
HOYA CORPORATION-8.40%15 219
DENTSPLY SIRONA INC-3.01%13 627
More Results